1lx6

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1lx6.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:1lx6.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1lx6| PDB=1lx6 | SCENE= }}
{{STRUCTURE_1lx6| PDB=1lx6 | SCENE= }}
-
'''Crystal Structure of E. Coli Enoyl Reductase-NAD+ with a Bound Benzamide Inhibitor'''
+
===Crystal Structure of E. Coli Enoyl Reductase-NAD+ with a Bound Benzamide Inhibitor===
-
==Overview==
+
<!--
-
Bacterial enoyl-ACP reductase (FabI) catalyzes the final step in each cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. Our efforts to identify potent, selective FabI inhibitors began with screening of the GlaxoSmithKline proprietary compound collection, which identified several small-molecule inhibitors of Staphylococcus aureus FabI. Through a combination of iterative medicinal chemistry and X-ray crystal structure based design, one of these leads was developed into the novel aminopyridine derivative 9, a low micromolar inhibitor of FabI from S. aureus (IC(50) = 2.4 microM) and Haemophilus influenzae (IC(50) = 4.2 microM). Compound 9 has good in vitro antibacterial activity against several organisms, including S. aureus (MIC = 0.5 microg/mL), and is effective in vivo in a S. aureus groin abscess infection model in rats. Through FabI overexpressor and macromolecular synthesis studies, the mode of action of 9 has been confirmed to be inhibition of fatty acid biosynthesis via inhibition of FabI. Taken together, these results support FabI as a valid antibacterial target and demonstrate the potential of small-molecule FabI inhibitors for the treatment of bacterial infections.
+
The line below this paragraph, {{ABSTRACT_PUBMED_12109908}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 12109908 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_12109908}}
==About this Structure==
==About this Structure==
Line 28: Line 32:
[[Category: Fabi]]
[[Category: Fabi]]
[[Category: Oxidoreductase]]
[[Category: Oxidoreductase]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 00:23:11 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jul 2 22:44:44 2008''

Revision as of 19:44, 2 July 2008

Image:1lx6.png

Template:STRUCTURE 1lx6

Crystal Structure of E. Coli Enoyl Reductase-NAD+ with a Bound Benzamide Inhibitor

Template:ABSTRACT PUBMED 12109908

About this Structure

1LX6 is a Single protein structure of sequence from Escherichia coli. Full crystallographic information is available from OCA.

Reference

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)., Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF, J Med Chem. 2002 Jul 18;45(15):3246-56. PMID:12109908

Page seeded by OCA on Wed Jul 2 22:44:44 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1lx6"
Personal tools